Coronary thrombolysis with recombinant tissue-type plasminogen activator: Patency rate and regional wall motion after 3 months  by Jang, Ik-Kyung et al.
JACC Vol. 8. No.6
December 1986:1455-60
REPORTS ON THERAPY
1455
Coronary Thrombolysis With Recombinant Tissue-Type Plasminogen
Activator: Patency Rate and Regional Wall Motion After 3 Months
IK-KYUNG JANG, MD, JOHAN VANHAECKE, MD, HILAIRE DE GEEST, MD,
MARC VERSTRAETE, MD, DESIRE COLLEN, MD, PHD, FRANS VAN DE WERF, MD
Leuven , Belgium
In a double-blind, placebo-controlled, randomized trial
the long-term (±3 months) effects of intravenous admin-
istration of recombinant tissue-type plasminogen acti-
vator (rt-Pa) versus placebo were compared in relation
to left ventricular function, coronary patency rate and
antigenicity in 28 patients with a first myocardial in-
farction. Patency rate of the infarct-related coronary
artery at the end of the rt-PA/placebo infusion and after
3 months of medical treatment (including oral antico-
agulant agents) was 86 and 71%, respectively, in the rt-
PA group, and 21 and 58%, respectively, in the placebo
group.
Regional wall motion of the infarct-related area was
quantitated with digital subtraction angiography. Intra-
patient comparisons revealed significant improvement in
Tissue-type plasminogen activator (t-PA) is a naturally oc-
curring serine protease with considerable fibrin-specific
thrombolytic properties (I ,2). It is produced on a large scale
by recombinant deoxyribonucleic acid (DNA) technology
(rt-PA). The biologic and thrombolytic properties of rt-PA
are very similar to those of human t-PA obtained from tissue
culture (3) . The initial favorable observations (4) on coro-
nary thrombolysis with native t-PA in patients with acute
myocardial infarction stimulated initiation of multicenter
randomized trials with rt-PA (4-8) . The overall results of
these trials indicate that, when administered intravenously,
rt-PA is a more effective thrombolytic agent than is strep-
tokinase. Moreover, at thrombolytic doses, considerably
less systemic activation of the fibrinolytic system was ob-
served with rt-PA than with streptokinase (9) .
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regional wall motion after 3 months in both the rt-PA
and placebo groups. The improvement in the rt-PA group
was not significantly greater than that in the placebo
group. Thirteen patients (10 with rt-PA and 3 with pla-
cebo) with persistent patency (both early and late) of the
infarct-related coronary artery showed a significant im-
provement of both global and regional left ventricular
function, while 8 patients (2 with rt-PA and 6 with pla-
cebo) with persistent occlusion showed no changes. An-
tibodies against rt-PA were not detected in serum 2 weeks
after the infusion, which is indicative of the lack of an-
tigenicity of rt-PA and allows for its repeated adminis-
tration.
(J Am Coil Cardiol1986;8:1455-60)
In the present study, we report long-term (± 3 months)
results of left ventricular function and coronary patency rate
after intravenous administration of rt-PA. These findings
were obtained in a subset of patients from one of the two
European rt-PA trials (8).
Methods
Treatment allocation. Twenty-eight patients with a first
myocardial infarction of less than 6 hours duration were
allocated in a double-blind manner to intravenous infusion
of placebo or 0.75 mg recombinant tissue-type plasminogen
activator (rt-PA)/kg over a period of 90 minutes. These
patients were a subset of a larger previously reported mul-
ticenter trial (8). Randomization was, however, carried out
per center to allow the investigation of separate aspects of
thrombolysis . The patient selection criteria are reported else-
where (7,8).
All patients received an intravenous bolus of 5,000 IV
heparin at the start of the experimental infusion. In those
patients in whom an open infarct-related coronary artery
was documented at the end of the experimental infusion,
anticoagulation was maintained with continuous intravenous
heparin (1,000 IV/h), followed by peroral dicoumarol for
0735-1097/86/$3 .50
1456 lANG ET AL.
THROMBOLYSIS WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR
lACC Vol. 8. No.6
December 1986: 1455-60
at least 3 months. In addition, these patients received high
doses of nitrates and nifedipine. At the time of discharge,
all patients were treated with a beta-blocking agent unless
this was contraindicated.
Informed consent was obtained in all patients. The study
protocol was approved by the Ethical Committee on Human
Research of the University of Leuven.
Angiographic evaluation. Coronary arteriography was
performed between 75 and 90 minutes after the start of the
rt-PA or placebo infusion. The suspected infarct-related
coronary artery was visualized first. Left ventricular angi-
ography was performed with the aid of digital subtraction
techniques. Digital images of the left ventricle in the 30°
right anterior oblique position were acquired and stored at
25 frames/s with a 256 X 256 X 10 bit pixel matrix (Oig-
itron, Siemens). Because of the limited amount of contrast
medium (15 to 20 ml) and the slow injection rate (5 to 6
mils), extrasystoles during injection could be avoided in
almost all patients.
Allpatients werereexamined afterapproximately 3 months,
using the same catheterization techniques. All cardioactive
medication was discontinued at least 18 hours before the
second catheterization. Coronary and left ventricular angio-
grams were analyzed without knowledge of the treatment
the patient had received. The angiographic criteria used to
assess patency of the infarct-related vessel are the same as
those in the European trials (7,8).
Analysis of left ventricular wall motion. Left ventric-
ular cavity borders were outlined manually on the subtracted
digital images at end-diastole and end-systole. Global ejec-
tion fraction was calculated from the traced silhouettes ac-
cording to the area-length method. For the evaluation of
regional wall motion, a radial coordinate system based on
the center point of the long axis of the left ventricular end-
diastolic silhouette was constructed. End-systolic and end-
diastolic contours were superimposed, and the computer
divided the silhouettes into 60 segmental radii with equal
6° angles (Fig. 1). Shortening fraction (SF) of each radius
was calculated by the formula: SF = [(0 - S)/O] X 100,
where 0 is the diastolic and S the systolic length of the
radius.
The normal values and standard deviation for each radius
were calculated from the digital left ventricular angiograms
obtained from 14 normal patients with atypical chest pain
and normal left ventricular function. To allow comparisons
among different regions of the heart and among different
patients, shortening fraction of each radius was standardized
and expressed in normal standard deviations (SO) using the
formula of Sheehan et al. (10): Z, = (SF; - Mj)/SDj, where
for chord i, SFj is the calculated shortening fraction, Z, is
the standardized SFj and M, and SD i are, respectively, the
mean shortening fraction and standard deviation in normal
subjects.
The left anterior descending coronary artery was consid-
ered to supply the territory from 36 to 228° clockwise from
the middle of the aortic valve, and the right coronary artery
(or dominant circumflex artery) the territory from 180 to
282°.
Blood analyses. Blood samples were collected in citrate
(final concentration 0.01 M) and aprotinin (200 kallikrein
inhibitory units/m!) at different time intervals. Fibrinogen
levels were determined by a coagulation rate assay (9) on
whole blood within 5 minutes after collection. Plasma was
then obtained by centrifugation, shell-frozen and stored at
- 20°e. The following assays were performed as described
elsewhere (9): fibrinogen, fibrinogen degradation products,
rt-PA antigen, factor V, plasminogen and O!rantiplasmin.
A serum sample for quantitation of antibodies against rt-
PA was obtained 2 weeks after the infusion. The samples
were tested for antibodies to rt-PA at Genentech, Inc.
by a radioimmune precipitation procedure. Briefly, iodine-
I25-labeled rt-PA was incubated overnight at 2 to 8°C with
diluted serum samples. Immunoglobulins were then precip-
itated with a polyvalent goat anti-human immunoglobulin
(Ig) antiserum, which had been shown to precipitate IgG,
IgM, IgA and IgE. A serum sample was positive for anti-
body to rt-PA when the counts precipitated were greater
than twice the counts precipitated by nonspecific binding of
a normal human serum. A rabbit positive control was used
to monitor the immunoreactivity of the iodine-125-labeled
rt-PA.
Results
Patient profile and clinical course. Of the 28 patients
who entered the study, 14 were allocated to recombinant
tissue-type plasminogen activator (rt-PA) infusion and 14
to placebo. Pertinent characteristics of the two groups are
summarized in Table I. No statistically significant differ-
Table 1. Baseline Characteristics of 28 Patients
Treatment Groups
rt-PA Placebo
No of patients 14 14
Male (no.) 13 12
Age (yr.) 54 ± 9 55 ± 10
Blood pressure (mm Hg)
Systolic 136 ± 28 143 ± 19
Diastolic 85 ± 16 91 ± 20
Heart rate (beats/min) 76 ± 18 70 ± 17
Time from onset of MI to 226 ± 77 207 ± 71
infusion (min)
Interval between two studies (wk) 14 ± 3 13 ± 4
Infarct site (no. of patients)
Anterior 6 7
Inferior 8 7
Data are mean ± SO. No significant differences between groups were
observed. MI = myocardial infarction; rt-PA = recombinant tissue-type
plasminogen activator.
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ences in any of these characteristics were observed. All
patients had electrocardiographic or enzymatic evidence, or
both, of acute myocardial infarction. No patient left the
study after randomization, and all patients underwent a sec-
ond catheterization, on average after 3 months. In one pa-
tient in the placebo group, coronary bypass surgery was
performed 2 weeks after the acute infarction because of
recurrent chest pain resistant to medical treatment. Signif-
icant bleeding (hematernesis, melena, gross hematuria or
excessive bleeding from the arteriotomy) was not observed.
All patients survived the acute episode and left the hos-
pital in stable clinical condition . After discharge, two pa-
tients in the rt-PA group and one patient in the placebo
group suffered from angina pectoris. All three patients had
a positive exercise test at the 3 month follow-up study. In
one of the rt-PA patients with angina pectoris coronary
bypass surgery was performed 6 weeks after the second
catheterization. Prolonged chest pain or other clinical signs
suggestive of reinfarction did not occur in any of the pa-
tients.
Angiographic findings. The great majority of the pa-
tients (nine in each group) presented with one vessel disease.
Two vessel disease was present in four patients receiving
rt-PA and in three patients receiving placebo, while three
vessel disease was found in one patient in the rt-PA group,
and in two patients in the placebo group (Table I) .
At the end of the experimental infusion, the infarct-
related vessel was patent in 12 (86%) of the 14 patients
allocated to rt-PA, and in 3 (21%) of the 14patients allocated
to placebo. At the time of the second angiographic evalu-
ation, the infarct-related vessel was still patent in 10 (71%)
of the 14 patients receiving rt-PA. In the placebo group,
late spontaneous recanalization of the infarct related artery
had occurred in 5 patients, yielding a total 3 month patency
rate of 58% (8 of 14 patients). In the one patient in the
placebo group in whom bypass surgery was performed after
thrombolysis, the infarct-related vessel (left anterior de-
scending coronary artery) was still patent at the time of
control angiography. Anterograde filling of the distal vessel
occurred by way of both the residual stenosis and the bypass
(internal mammary artery).
Pairs of digital left ventricular angiograms, obtained im-
mediately after the experimental infusion and 3 months later.
were available in all 28 patients. Changes in global and
regional left ventricular function were analyzed according
to the treatment administered (rt-PA or placebo) and ac-
cording to early and late patency of the infarct-related artery
irrespective of treatment.
The global ejection fraction increased in both treatment
groups: from 58 ± 14 to 64 ± 10% in the rt-PA group,
and from 54 ± 14 to 60 ± 10% in the placebo group.
These differences, however, were not statistically signifi-
cant. Individual changes in regional left ventricular function
in the two treatment groups are shown in Figure 2. The
regional wall motion of the infarct-related area improved
significantly in both groups (from - 2.38 ± 0.88 to
- 1.73 ± 0.92 normal standard deviations in the rt-PA
group, and from - 2.87 ± 0.84 to - 2.19 ± 0.63 normal
standard deviations in the placebo group). However, no
significant differences in global or regional left ventricular
function could be detected between the two treatment groups.
The left ventricular and coronary angiograms were also
analyzed on the basis of patency (regardless of the type of
intervention). Global ejection fraction improved signifi-
cantly in patients whose infarct-related vessel was patent
both at the end of the experimental infusion and after 3
months (from 55 ± 15 to 67 ± II %; P < 0.02). No
significant changes were observed in patients with a per-
sistent occlusion (from 59 ± 12 to 57 ± 8%). Similarly,
a significant improvement in regional left ventricular func-
tion was found in the patients with an open artery (from
- 2.51 ± 0.97 to - 1.62 ± 0.95 normal standard devia-
tions), whereas no significant changes were observed in
patients with a persistent occlusion (from - 2.67 ± 0.78
to - 2.38 ± 0.66 normal standard deviations) (Fig. 3). In
the five patients in the placebo group with early coronary
occlusion but late reopening, an improvement in both global
ejection fraction (from 48 ± 13 to 58 ± 6%) and regional
wall motion (from -2.98 ± 0.95 to -2.17 ± 0.44 normal
standard deviations) was observed, but these changes were
not statistically significant.
Blood analyses. Intravenous administration of rt-PA re-
sulted in a plasma level of 1.2 ± 0.8 ILg/ml toward the end
of the infusion, when the fibrinogen level measuredon whole
blood had decreased to 41 ± 35% (mean ± SD) of the
preinfusion level, and that measured in plasma to 55 ±
30%. In the rt-PA treatment group, fibrinogen-fibrin deg-
radation products increased to 0.066 ± 0.087 mg/rnl, and
Q'rantiplasmin, plasminogen and factor V decreased on av-
erage to between 40 and 60% of the preinfusion level. The
changes in the placebo group were 20% for factor V and
less than )0% for the other variables.
Antibodies against rt-PA were determined in serum col-
lected2 weeks after the infusion in 12of the 14 rt-PA-treated
patients. All samples were found to be negative.
Discussion
Coronary patency and reocclusion rates. In the present
study, patency rates of the infarct-related vessel at the end
of the intravenous infusion of recombinant tissue-type plas-
minogen activator (rt-PA) and after 3 months in 14 patients
with acute myocardial infarction were 86 and 71%, respec-
tively. These patency rates are comparable with the best
results obtained with intracoronary streptokinase (II).
In the placebo group, patency rates at the end of the
infusion and at late follow-up study were 2 I% (3 of 14
patients) and 58% (8 of 14 patients), respectively. Thus,
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Figure 1. Digital left ventricular angiograms in 30°
right oblique position. Top, Obtained at the end of
the experimental infusion of recombinant tissue-type
plasminogen activator in a patient with acute anterior
myocardial infarction and a patent left anterior de-
scending coronary artery. Bottom, Obtained at 3
months in the same patient. There is persistent pat-
ency of the left anterior descending coronary artery.
A marked improvement in systolic shortening of the
segmental radii in the infarct area is observed. A =
end-diastolic contour; B = end-systolic contour;
C = superimposed end-diastolic and end-systolic
contours with radial coordinate system: 60 segmental
radii with 6° angles; D = shortening fraction of the
diffent radii from 0 to 360°. There is akinesia and
dyskinesia in the infarct area (segmental radii 42 to
180°).
B
ING
180
OEG
90
'--__'-_ -''--_-''--------l
270 360
o
l.:J
Z
Z
....
>-
a:
o
J:
III
~ -so
c
late spontaneous thrombolysis occurred in 5 of II patients
receiving placebo (46%), Rentrop et al. (12) reported an
even higher spontaneous reopening rate of the infarct-related
vessel after 2 weeks (in 10 [77%] of 13 patients).
The reocclusion rate of 17% (2 of 12 patients) in the rt-
PA group is not different from that reported after intracor-
onary or intravenous streptokinase (11). This suggests that
the less pronounced hemostatic defect after rt-PA infusion
is not associated with a higher risk of rethrombosis, provided
that adequate anticoagulation is maintained.
Left ventricular function. In both the placebo and rt-
PA groups, improvement in global ejection fraction (not
statistically significant) and regional wall motion (statisti-
cally significant) was found, These findings differ from those
lACC Vol. 8, No.6
December 1986:1455-60
l ANG ET AL.
THROMBOLYSIS WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR
1459
/
.. -0
a more sensitive technique than radionuclide ventriculog-
raphy . The lack of a significantly greater benefit in the rt-
PA group as compared with the placebo group is not sur-
prising in view of our small sample size and the inherent
type II error. However, becau se of the predetermined num-
ber of patients in the study, it was not possible to enter
additional patients .
When the data are analyzed on the basis of patency ,
irrespective of treatment allocation , patients with an open
infarct-related vessel in the acute phase and at late follow-
up showed a significant improvement in both global and
regional left ventricular function , while patients with a per-
sistent occlusion showed no changes. These results are very
similar to those obtained wiith intracoronary streptokinase
by Sheehan et al. (14).
Although it is generally believed that functional benefit
from thrombolytic treatment may be confined to patients
treated very early after the onset of symptoms (15), there
is some indirect evidence that late reopening of the infarct-
related coronary artery may also be advantageous. For ex-
ample, a recent analysis (16) of pooled mortality data from
six trials with intravenous streptokinase revealed a similar
reduction in mortality in patients treated very early «6
hours) or late (> 12 hours) after the onset of symptoms. The
improvement in left ventricular function in the five placebo-
treated patients with late reperfu sion , although not statis-
tically significant, and the lack of any improvement in pa-
tients with a persistent obstruction also suggest a potential
beneficial effect of late spontaneous reperfusion.
Blood analyses. The changes in fibrinogen, fibrinogen
degradation products, plasminogen , Q'rantiplasmin and fac-
tor V in the present subgroup of patients were very similar
to the overall changes reported elsewhere (9). A decrease
in fibrinogen observed when measured immediately on whole
blood was similar to that observed in frozen plasma collected
on apoprotin.
Antibodies against rt-PA were not detected in serum ob-
tained 2 weeks after the infusion . These results confirm the
lack of antigenicity observed with natural t-PA (17) and
indicate the possibility of repeated effective thrombolysis
with rt-PA .
Conclusions. From this study the following conclusions
can be drawn . I) After intravenous administration of re-
combinant tissue-type plasminogen activator, patency rates
of the infarct-related coronary artery are comparable with
those after intracoronary streptokinase . 2) Under medical
post-thrombolytic treatment (oral anticoagulant agents , ni-
trates and nifedipine), the great majority of the open vessels
remain patent after 3 months (reocclusion rate 17%) 3) In
nearly half of the patients with an occluded vessel, late
spontaneous endogenous thrombolysis occurs, which may
also have a beneficial effect on left ventricular function. 4)
A significant improvement in global and regional left ven-
tricular function can be demonstrated at late follow-up study
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Figure 3. Analysis of changes in regional wall motion according
to coronary artery patency. Abbreviations and format as in Fig-
ure 2.
of Khaja et a!. (13), who did not observe changes in global
or regional left ventricular function at late follow-up study
in a control group and in patients treated with intracoronary
streptokinase (intrapatient comparisons). Our finding of a
significant improvement in regional wall motion may be due
to the use of digital subtraction angiography, which may be
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Figure 2. Analysis of changes in regional wall motion according
to treatment. Each circle or triangle represents the mean stan-
dardized shortening fraction of the segmental radii in the infarct
area of an individual patient (expressed in normal standard devia-
tions (SO». Open circles indicate patients in the recombinant
tissue-type plasminogen activator (rt-PA) group with a patent in-
farct-related vessel. Closed circles indicate patients in the rt-PA
group with an occluded infarct-related vessel. Open triangles
indicate patients in the placebo group with a patent infarct-related
artery. Closed triangles indicate patients in the placebo group
with an occluded infarct-related artery . Closed squares are the
mean values of the groups.
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in patients whose infarct-related vessel is recanalized (either
spontaneously or after the administration of rt-PA). 5) No
improvement in left ventricular function is observed in pa-
tients wiht persistent occlusion of the infarct-related coro-
nary artery. 6) Because of the lack of antigenicity of rt-PA,
repeated dose-related effective thrombolysis with this agent
appears to be possible.
We are grateful to Tony Chen, PhD, Genentech Inc., for performing the
assays of antibodies against rt-PA.
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